Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 3/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 3/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.41 |
| ▸ | PGR | P06401 | 15/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.40 |
| ▸ | AR | P10275 | 7/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8587938 | 1.00 | PDK1 (0.41) | PDK1PDK2PDK3PDK4PGR | |
| SCHEMBL8536387 | 0.90 | PGR (0.51) | PGRNR3C1ARCYP3A4SLC6A4 | |
| SCHEMBL8639950 | 0.85 | PGR (0.35) | PGRNR3C1ARCYP3A4 | |
| SCHEMBL8541047 | 0.80 | PGR (0.48) | PGRNR3C1ARCYP3A4 | |
| SCHEMBL10449008 | 0.79 | PDK1 (0.52) | PDK1PDK2PDK3PDK4PGR | |
| SCHEMBL8768109 | 0.79 | PGR (0.47) | PGRNR3C1ARCYP3A4 | |
| SCHEMBL8536181 | 0.79 | PGR (0.49) | PGRNR3C1ARCYP3A4ADORA3 | |
| SCHEMBL9171269 | 0.78 | CYP17A1 (0.33) | PGRARCYP3A4 | |
| SCHEMBL8536118 | 0.77 | PGR (0.51) | PGRNR3C1ARCYP3A4ADORA3 | |
| SCHEMBL9019827 | 0.75 | NR3C1 (0.59) | PGRNR3C1ARCYP3A4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0404283-B1 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AG (DE) | 1996-05-08 | — | — | EP | claimed |
| EP-0404283-A2 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-12-27 | — | — | EP | claimed |
| US-5843933-A | 11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-01 | — | — | US | disclosed |
| US-5728689-A | ANTIGESTAGENIC EFFECT | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-03-17 | — | — | US | disclosed |
| EP-0404283-B1 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AG (DE) | 1996-05-08 | — | — | EP | disclosed |
| EP-0404283-A2 | 11-Beta-aryl-4-estrene, method for its production and its use as a medicine | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-12-27 | — | — | EP | disclosed |